Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04408001
Other study ID # 2020-COVID19-04
Secondary ID 2020-A01019-30
Status Completed
Phase
First received
Last updated
Start date June 4, 2020
Est. completion date March 15, 2022

Study information

Verified date April 2023
Source Direction Centrale du Service de Santé des Armées
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

COVID-19 is a pathology linked to the SARS-CoV-2 virus, a new virus of the coronaviridae family that emerged in China in December 2019 before rapidly becoming a pandemic according to the WHO on March 11, 2020. The epidemic affected France from February 2020. On February 24, a patient hospitalized at Percy hospital was the cause of a major nosocomial epidemic, potentially responsible for more than 250 symptomatic people in the hospital as of April 6. The outbreak was identified by Percy hospital management on March 16, and barrier measures were immediately put in place. From March 20, a mixed investigation unit set up a chain of nasopharyngeal swabs for Percy hospital staff. A COVID-19 case reporting unit was set up at Percy hospital in response to the identification of the outbreak within the hospital. This unit carried out rapid identification and regular follow-up until the return to work of the staff. Thus all symptomatic patients are identified and the COVID-19 case census cell will follow all Percy hospital staff, including volunteers recruited to deal with the epidemic, throughout the duration of the epidemic. This population, captive by nature, will be one of the few described in the world during this epidemic. Current data on short-, medium- and long-term immunity induced by COVID-19 infection are fragmentary, as is the existence of a large asymptomatic population, making it difficult to cut the chains of transmission in the absence of an effective diagnostic tool. Another important issue is the quality of immunity induced by the infection, as it conditions the future of the pandemic, which could become endemic and recurrent if immunity were not sterilizing. As yet unpublished data in primates show that in the primate model re-infection is not possible in the short term, while patients cured from the Wuhan epidemic seem to be detected again positive for virus shedding. The objective of this study is to characterize the immunity (systemic and local) induced by SARS-Cov-2 infection among Percy hospital staff who are at high risk of contamination even in a period of confinement.


Recruitment information / eligibility

Status Completed
Enrollment 499
Est. completion date March 15, 2022
Est. primary completion date March 15, 2022
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years of age or older; - Military or civilian or contactual volunteer on duty at Percy hospital during the COVID-19 pandemic. Exclusion Criteria: - Individuals who have displayed a severe form of early-onset COVID-19 who required intensive care management or hospitalization; - Presence of factors modulating immunity with congenital or acquired immunosuppression: - Medication: cancer chemotherapy, immunosuppressive drugs, biotherapy, corticosteroids - Uncontrolled HIV infection or CD4 <200/mm3 infection - History of solid organ or hematopoietic stem cell transplants

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Clinical interview
At each study visit, participants will be questioned by a physician about their persistent symptoms or the existence of intercurrent infections that may resemble COVID-19.
Biological:
Blood collection
At each study visit, 1 EDTA tube for complete blood count 3 dry tubes with gel for serology, serum neutralisation test and serum library 1 cell preparation tube for the separation of immune cells within the circulating blood will be collected.
Saliva collection
At each study visit, a saliva sample will be collected for the determination of IgA antibodies.

Locations

Country Name City State
France Hôpital d'Instuction des Armées Percy Clamart

Sponsors (1)

Lead Sponsor Collaborator
Direction Centrale du Service de Santé des Armées

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Induced SARS-CoV2 immunity The presence of induced immunity will be identified by an Ig family switch on the first two serologies with a high titre of specific IgG and disappearance of IgM. At day 21 (compared to enrollment [Day 0])
Primary Long-term protection of induced SARS-CoV2 immunity at 6 months The presence of induced immunity will be identified on serology analysis at 6 months. 6 months following enrollment
Primary Long-term protection of induced SARS-CoV2 immunity at 1 year The presence of induced immunity will be identified on serology analysis at 1 year. 1 year following enrollment
Primary Anti-SARS-CoV2 antibodies kinetics in blood throughout the study Kinetics of anti-SARS-CoV-2 antibodies using ELISA technique on serum samples from enrollment (Day 0) to 1 year after enrollement From enrollment (Day 0) to 1 year after enrollement
Primary Anti-SARS-CoV2 antibodies kinetics in saliva throughout the study Kinetics of anti-SARS-CoV-2 antibodies using ELISA technique on saliva samples from enrollment (Day 0) to 1 year after enrollement From enrollment (Day 0) to 1 year after enrollement
Primary Kinetics of serum neutralization in blood throughout the study Kinetics of serum neutralization against SARS-CoV-2 positive using ELISA technique on serum samples from enrollment (Day 0) to 1 year after enrollement. From enrollment (Day 0) to 1 year after enrollement
Secondary Anti-SARS-CoV2 seroprevalence in asymptomatic individuals at Day 0 Anti-SARS-Cov2 seroprevalence measured in serum samples collected at Day 0. At enrollment (Day 0)
Secondary Anti-SARS-CoV2 seroprevalence in asymptomatic individuals at Day 21 Anti-SARS-Cov2 seroprevalence measured in serum samples collected at Day 21. At Day 21
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04446065 - Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers Phase 2/Phase 3
Completed NCT04419025 - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease Phase 2
Not yet recruiting NCT04400019 - Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) Phase 2/Phase 3
Completed NCT04463004 - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Phase 2
Completed NCT04446429 - Anti-Androgen Treatment for COVID-19 N/A
Completed NCT04402957 - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) Phase 2
Recruiting NCT04581148 - SARS-CoV2 Antibodies in Pediatric Patients (COVID-19)
Recruiting NCT04441372 - Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection
Terminated NCT04371978 - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Phase 3
Completed NCT04530604 - Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS) Phase 1
Active, not recruiting NCT04635605 - Methylene Blue Treatment of COVID-19 Phase 2
Recruiting NCT04395599 - Risk of Air Contamination During Visceral Surgery in COVID19 Patients N/A
Recruiting NCT04472585 - Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients Phase 1/Phase 2
Active, not recruiting NCT04411433 - Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19 Phase 3
Completed NCT04359706 - Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19
Recruiting NCT04395794 - SARS-CoV-2 Disguise Study
Completed NCT04386551 - Detection of COVID-19 in Saliva Collection
Recruiting NCT04403269 - NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE Phase 2
Withdrawn NCT04379492 - A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19 Phase 2
Completed NCT04366934 - Study of the Pathogenesis of Olfactory Disorders in COVID-19